Short answer
Vaxcyte, Inc. (PCVX) filed an 8-K current report with the SEC on September 3, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 7.01 (Regulation FD Disclosure). David McAvoy appointed Chief Legal Officer, Chief Compliance Officer, and Corporate Secretary effective August 31, 2026.
Vaxcyte, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- David McAvoy appointed Chief Legal Officer, Chief Compliance Officer, and Corporate Secretary effective August 31, 2026
- Mikhail Eydelman remains Senior Vice President and General Counsel
- Expanded legal and compliance leadership may support regulatory execution as Vaxcyte advances its vaccine pipeline
Item 7.01 · Regulation FD Disclosure
- Appointment of Chief Medical Officer and Chief Legal Officer, signaling leadership expansion
- Narrowed timing guidance for VAX-31 OPUS-1 topline data, improving visibility around the clinical readout
- VAX-31 clinical results remain a key near-term catalyst for Vaxcyte valuation and investor sentiment
- Details of the revised guidance and executive appointments appear in Exhibit 99.1
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Vaxcyte, Inc. 8-K filings
Get the next PCVX 8-K as it lands
Follow PCVX for push alerts, or ask the research agent what this filing means.